- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02297802
A Single Patient IND for PD-0325901
November 24, 2014 updated by: Sharp HealthCare
A Phase I Single Patient IND for PD-0325901
The purpose of this study is to provide access for a single patient to PD-0325901 who was previously enrolled in a phase I clinical trial.
Study Overview
Status
No longer available
Intervention / Treatment
Study Type
Expanded Access
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Sharp HealthCare
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Prior treatment with PD-0325901 with ongoing response
Exclusion Criteria:
- none
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Actual)
July 1, 2013
Study Completion (Actual)
July 1, 2013
Study Registration Dates
First Submitted
May 12, 2014
First Submitted That Met QC Criteria
November 20, 2014
First Posted (Estimate)
November 21, 2014
Study Record Updates
Last Update Posted (Estimate)
November 26, 2014
Last Update Submitted That Met QC Criteria
November 24, 2014
Last Verified
November 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- 130596 SHRP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prior Treatment With PD-0325901 With Ongoing Clinical Response
-
Gruppo Italiano Malattie EMatologiche dell'AdultoCompletedPatients With CLL Relapsing After an Initial Response (CR, PR ≥ 6 Months) Following no More Than Two Prior Treatment Lines; or | Patients With CLL Refractory (SD, PD or CR/PR < 6 Months) Following no More Than Two Prior Treatment LinesItaly
-
AmgenCompletedAny Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical TrialCanada, Spain, United States, Germany, Austria, France, Greece, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, South Africa, Switzerland, United Kingdom
-
Samsung Medical CenterRecruitingHistologically Confirmed Metastatic or Locally Advanced Breast Cancer With no Radical Topical Treatment Available | If There is Liver Metastasis, Which the Researcher Believes Will be Difficult to Evaluate the Response Accurately With Bone Metastasis or CTSouth Korea
-
Mohammed Nasser AlhajjMansoura UniversityCompletedTo Evaluate the Clinical and Radiographic Effect of Platelet-rich Fibrin in Treatment of Necrotic Permanent Teeth with Open ApicesEgypt
-
Guiying WangNot yet recruitingPatients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment
-
Yunnan Cancer HospitalRecruitingClinical Complete Response Rate With Negative MRDChina
-
Second Affiliated Hospital, School of Medicine,...Active, not recruitingElectroacupuncture Combined With Paclitaxel Protein-bound and PD-1 Antibody for Second-line Treatment of HER2 Negative, pMMR/MSS Advanced Gastric CancerChina
-
Fudan UniversityRecruitingLymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)China
-
ACADIA Pharmaceuticals Inc.CompletedTreatment of Depression in Adults With Parkinson's Disease (PD)United States
Clinical Trials on PD-0325901
-
University of Alabama at BirminghamCompletedNeurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PNUnited States
-
PfizerTerminatedCarcinoma, Non-Small-Cell LungUnited States
-
Kevin Kim, MDRecruitingMetastatic Melanoma | Advanced Unresectable MelanomaUnited States
-
SpringWorks Therapeutics, Inc., a healthcare company...Active, not recruitingPlexiform Neurofibroma | Neurofibromatosis Type 1 (NF1)United States
-
St. Jude Children's Research HospitalSpringWorks Therapeutics, Inc.RecruitingLow-Grade Glioma | Recurrent Low-Grade Glioma | Progressive Low-Grade GliomaUnited States
-
BeiGeneSpringWorks Therapeutics, Inc.CompletedSolid Tumor, AdultAustralia, United States
-
Dana-Farber Cancer InstituteCompletedSolid Tumors | KRAS Mutant Non-Small Cell Lung CancerUnited States
-
SpringWorks Therapeutics, Inc., a healthcare company...RecruitingHealthy | Hepatic ImpairmentUnited States
-
PfizerTerminatedMelanoma | Breast Neoplasms | Colonic NeoplasmsUnited States
-
SpringWorks Therapeutics, Inc.Terminated